GeneDx Hldgs Q4 Adj EPS $(0.69) Beats $(0.75) Estimate, Sales $57.42M Beat $55.43M Estimate
Portfolio Pulse from mahesh@benzinga.com
GeneDx Holdings (WGS) reported Q4 adjusted EPS of $(0.69), surpassing the $(0.75) estimate, and sales of $57.42M, exceeding the $55.43M estimate. This represents a significant improvement in losses compared to the same period last year, but a slight decrease in sales.
February 20, 2024 | 10:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GeneDx Holdings reported a significant improvement in Q4 earnings, beating both EPS and sales estimates, indicating a strong financial performance.
GeneDx Holdings' Q4 earnings report shows a substantial improvement over last year's losses and beats analyst estimates for both EPS and sales. This positive performance, especially the significant reduction in losses, is likely to instill investor confidence and could lead to a short-term uptick in the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100